Message from the President & CEO

As our 25^th anniversary year continues, Beardsworth’s reputation as a provider of exceptional clinical research services in oncology and complex clinical trials is stronger than ever.

By engaging highly qualified professionals to manage our clients’ critical needs, we remain strongly positioned to answer their call for advanced expertise. In fact, expertise, discipline and commitment are more important than ever as trials are increasingly challenged by stricter protocol and study designs, competitive trials, and are under ever more rigorous timelines and financial constraints.

We continue to differentiate ourselves among CROs through our active pursuit of demanding studies. We look for oncology and other complex Phase 1-4 studies that require a higher level of performance...that demand our best.

While all clinical studies are complex, the most challenging often involve investigational treatments for diseases that pose the greatest risk to human health. Success in these studies requires specialized expertise and uncommon dedication. Our reputation as the CRO of choice for challenging clinical studies is based on our willingness to take on complexity, to take the risks needed to continue making meaningful contributions to healthcare.

Some examples of projects in which we are engaged, most of which involve our full service capabilities, reflect this caliber of project complexity:

• Global Phase 2 and 3 Studies in Ovarian Cancer
• Phase 2 Study in Metastatic Breast Cancer
• Global Drug/Device Oncology Vaccine Study in Cervical Neoplasia
• Phase 2 Study in a Breast Cancer Diagnostic
• Global Rescue Study in an Orphan Endocrine Indication
• Phase 3 Study in a Bio-Defense Vaccine
• Global Phase 3 Study in Ovarian Cancer
• Safety Program in a Transplant Study

Each of these projects requires a specific approach unique to each Client, patient population and study parameter. Each requires an experienced team of professionals to address its individual complexities, and to transform it into sound strategy and execution. Each requires a high level of dedication and commitment.

As a company, Beardsworth continues to grow. In terms of fiscal performance, we are once again on track to grow revenues by 15-20% in 2011. In addition, we continue to add to our oncology and complex trial expertise by increasing our professional staff in equal measure. And, our commitment to respond to the established trend in global trial activity is reflected in OncologyOne^®, our next-generation global alliance across Europe and the Asia/Pacific regions.

Over the coming months, you can meet Beardsworth’s professionals at the following industry conferences - http://www.beardsworth.com/e_events.asp

In closing, I offer the following amended version of the insights I recently shared with the Beardsworth leadership team:

"We’ve never been in a stronger, more competitive position to provide industry-leading service and support than we are today. We’re strong today. And we’ll keep getting stronger because our professionals have the specialized skills, expertise and commitment needed to provide successful, cost-effective services for the conduct of oncology or other complex clinical studies."

Michael J. O’Brien
President & CEO